Overview
OM1 provides healthcare analytics and AI-driven insights using real-world data to improve patient outcomes. It collects data from sources like electronic health records, insurance claims, and patient registries to create real-world evidence that informs decisions for chronic diseases and treatments. Its flagship product, Aspen, automates evidence generation by applying AI to identify patients with specific conditions and predict treatment outcomes, helping pharma companies, healthcare providers, and IDNs make better decisions about care and therapy development. Compared with others, OM1 emphasizes scalable real-world data fusion, automated evidence generation, and strong collaborations with large healthcare organizations to validate long-term outcomes. The company aims to advance predictive medicine and support the development and optimization of treatments, ultimately improving patient care and outcomes.
Work here?Claim your company
Simplify's take
What believers are saying
- OM1 expanded into Europe in 2025, opening new pharma and payer accounts.
- Hologic's 2026 FDA approval showcases OM1's automation for large regulatory studies.
- New PhenOM products broaden monetization across screening, risk, and treatment-effect workflows.
What critics are saying
- PhenOM's metrics come from OM1's own cloud; external validation remains limited in 2026.
- Life-sciences budgets and single-study revenue depend on a few pharma and device customers.
- If health systems reject OM1's model, the company becomes a premium analytics vendor, not a platform.
What makes OM1 unique
- PhenOM validated 1,770 outcomes on 400 million patient records in November 2026.
- OM1 supported Hologic's 650,000-patient FDA submission, proving regulatory-grade evidence execution.
- Catherine Richards now runs four business units, tightening product, science, and commercialization.
Help us improve and share your feedback! Did you find this helpful?
